4th International Scientific and Family Conference July 2015

All of us on the board of ISMRD are honored and excited to once again sponsor a combined scientific and family conference for glycoprotein diseases in July 2015. The conference, Glycoproteinoses: Fourth International Conference on Advances in Pathogenesis and Therapy will be held on July 23–26 2015 in St. Louis, Missouri, USA. More detailed information on the conference agenda and registration information will be coming soon. We would like to invite all interested families and investigators and industry to attend this conference. If you wish to be added to the mailing list please send us your details.

Fucosidosis

General Description

MatthewFucosidosis is caused by the lack of the enzyme alpha-fucosidase.

There are two different types of fucosidosis. They are characterized by the age of onset and type of physical and mental manifestations.

  • Type I usually presents in the first 3–18 months of life with features typical of lysosomal storage diseases including coarsening of facial features, large liver, spleen and/or heart and dysostosis multiplex (abnormal bone formation that is found in multiple bones of the body) seen on x-ray. Cherry red spots may be present on ophthalmology evaluation. Cherry red spots are spots on the retina that have storage of sugar chains, causing the remainder of the healthy retina to look brighter. Mental retardation and seizures are also present. Additionally, sweat chloride may be elevated.
  • Type II fucosidosis presents between 12 and 24 months of life. Individuals usually have mild coarsening of facial features, dysostosis multiplex, mental retardation enlarged liver, spleen and/or heart involvement. In addition, angiokeratomas (superficial blood vessel dilation over which wart like growths occur) may be present. Another feature of type II fucosidosis is the presence of twisted blood vessels within the membrane covering of the eyeball and inner eyelid.

In the past, researchers described two types of this condition based on symptoms and age of onset, but current opinion is that the two types are actually a single disorder with signs and symptoms that range in severity.

For further information read the 'fact sheet'. 

How common is Fucosidosis?

Fucosidosis is a very rare lysosomal storage disease and though the incidence worldwide is not known with any certainty, it is estimated to affect less than 1:2,000,000.

Is there a treatment for Fucosidosis?

Individuals with Fucosidosis should have routine follow-up with Genetics, Neurology, Ophthalmology, and other specialists as needed. Currently, there is no cure to stop the progression of symptoms of Fucosidosis and treatment is aimed at addressing the individual problems as they arise.

Medical and Research information

  • GeneTests: A list of labs testing for Fucosidosis.
  • Genetic Home Reference: This has an excellent description of Fucosidosis with good references to other information and resources.
  • OMIM: Technical information about the genetics of Fucosidosis. OMIM is a site developed for scientists and medical specialists and contains both general and highly technical information. Access to this site is free.
  • Orphanet: A database dedicated to information on rare diseases and orphan drugs. Access is free of charge.
  • Clinicial Trials. A registry of federally and privately supported clinical trials conducted in the United States and around the world. This site gives information about each trial’s purpose, who may participate and the location.

Patient Support Groups

  • ISMRD is the international advocate for Glycoprotein Storage Diseases.
  • Lysosomal Diseases New Zealand is the support group for families living in New Zealand.
  • UK MPS Society is the support group for MPS and related disease in the United Kingdom.
  • Other MPS Societies around the world may also offer some support.